

# Aly-Khan A Lalani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7137064/publications.pdf>

Version: 2024-02-01

83  
papers

1,456  
citations

471061

17  
h-index

414034

32  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2735  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022, 207, 16-24.	0.2	31
2	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747.	3.2	11
3	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
4	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS398-TPS398.	0.8	3
5	Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2022, 40, 316-316.	0.8	1
6	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 304-304.	0.8	0
7	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 210-218.	0.9	4
8	Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211086.	1.4	15
9	Emerging Biomarker-Guided Therapies in Prostate Cancer. <i>Current Oncology</i> , 2022, 29, 5054-5076.	0.9	10
10	Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 15, 281-286.	0.3	7
11	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.	0.2	3
12	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, 82-95.	0.2	0
13	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 773.	3.4	21
14	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 521-530.	0.9	8
15	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, 353-358.	0.3	2
16	The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	1
17	PD40-07�fCLINICAL OUTCOMES AND ADVERSE EVENTS AFTER FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. <i>Journal of Urology</i> , 2021, 206, .	0.2	1
18	Cabozantinib real�world effectiveness in the first�through fourth�line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	1.3	22

#	ARTICLE	IF	CITATIONS
19	The emerging treatment landscape of advanced urothelial carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, Publish Ahead of Print, 247-252.	0.5	1
20	Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. <i>Current Oncology</i> , 2021, 28, 226-232.	0.9	2
21	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , 2020, 6, 37-40.	1.6	6
22	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	2.6	59
23	From Famine to Feast: Treating Urinary Malignancies in the Immunotherapy Era. <i>European Urology Focus</i> , 2020, 6, 1-2.	1.6	2
24	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020, 3, 695-699.	2.6	30
25	Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e887.	0.4	0
26	211: Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCIS). <i>Radiotherapy and Oncology</i> , 2020, 150, S89-S90.	0.3	0
27	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210.	1.3	50
28	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , 2020, 6, 293-306.	0.8	4
29	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11
30	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 639-639.	0.8	3
31	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS761-TPS761.	0.8	12
32	Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2020, 38, 682-682.	0.8	2
33	Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade. , 2020, , .		0
34	Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2020, 38, 633-633.	0.8	0
35	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 642-642.	0.8	9
36	Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 620-620.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). <i>Annals of Oncology</i> , 2019, 30, v396.	0.6	4
38	CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2019, 30, v885.	0.6	12
39	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.	0.3	10
40	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , 2019, 76, 852-860.	0.9	9
41	Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 122-129.	0.3	3
42	A A Canadian consensus forum on the management of patients with advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, E137-E149.	0.3	15
43	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346.	5.8	139
44	Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. <i>Canadian Urological Association Journal</i> , 2019, 14, E154-E158.	0.3	15
45	Capturing recurrence in urothelial carcinoma: â€œmore than meets the eyeâ€. <i>Translational Andrology and Urology</i> , 2019, 8, S524-S527.	0.6	0
46	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2019, 14, E115-E125.	0.3	3
47	Systemic treatments for metastatic urothelial carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 201-208.	0.9	12
48	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019, 75, 100-110.	0.9	178
49	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4516-4516.	0.8	6
50	Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 566-566.	0.8	9
51	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2019, 37, 568-568.	0.8	3
52	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1238-1242.	2.9	33
53	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018, 6, 402-408.	1.6	56
54	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 13, 166-174.	0.3	10

#	ARTICLE	IF	CITATIONS
55	Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). <i>Annals of Oncology</i> , 2018, 29, viii311.	0.6	9
56	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 707-712.	2.9	28
57	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018, 118, 1434-1441.	2.9	34
58	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
59	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
60	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. <i>Kidney Cancer</i> , 2018, 2, 31-36.	0.2	10
61	JAVELIN: avelumab another spear to fight urothelial carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 5-7.	5.1	2
62	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 607-607.	0.8	12
63	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 626-626.	0.8	1
64	CD73 expression in primary and metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 643-643.	0.8	1
65	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-667.	0.8	0
66	Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 629-629.	0.8	0
67	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-“Lymph Node Distant Metastasis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1089-e1094.	0.9	3
68	Pan-urologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49
69	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 724-732.	0.9	34
70	Immunotherapy in the Elderly. <i>European Urology Focus</i> , 2017, 3, 403-412.	1.6	16
71	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112.	0.3	32
72	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37

#	ARTICLE	IF	CITATIONS
73	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). <i>Annals of Oncology</i> , 2017, 28, v314-v315.	0.6	0
74	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4573-4573.	0.8	1
75	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017, 35, 468-468.	0.8	4
76	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017, 8, 103428-103436.	0.8	19
77	Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 493-493.	0.8	0
78	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16078-e16078.	0.8	0
79	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16065-e16065.	0.8	0
80	Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12000-e12000.	0.8	0
81	Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. <i>Annals of Oncology</i> , 2016, 27, vi285.	0.6	1
82	Abstract P3-07-13: Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. , 2015, , .		0
83	Manifestations of Von Hippel Lindau syndrome: a retrospective national review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 291-296.	0.2	10